International trials of blood thinners pause enrollment of critically ill COVID-19 patients
Three international partners have come together in an unprecedented collaboration resulting in a multiple platform randomised controlled trial. The partners include REMAP-CAP - the Randomised, Embedded, Multi-factorial Adaptive Platform Trial for Community-Acquired Pneumonia. REMAP-CAP is a nationally prioritised COVID-19 study, and as of November 2020 75% of all study participants had been recruited in the UK through the NIHR’s Clinical Research Network (CRN).
The other partners are Accelerating COVID-19 Therapeutic Interventions and Vaccines-4 (ACTIV-4) and Antithrombotics Inpatient and Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC).
The three trials, which span four continents, have the common goal of assessing the benefit of full doses of blood thinners to treat moderately ill or critically ill adults hospitalised for COVID-19, compared with a lower dose often used to prevent blood clots in hospitalised patients.
As is normal for clinical trials, these trials are overseen by independent boards that routinely review the data and are composed of experts in ethics, biostatistics, clinical trials, and blood clotting disorders.
At the recommendation of the oversight boards, patients who do not require ICU care at the time of enrollment will continue to be enrolled in the trial. Whether the use of full-dose compared with low-dose blood thinners leads to better outcomes in hospitalised patients with less severe disease remains a very important question.
“We want to thank all the patients, clinicians, and research staff who have contributed to advancing knowledge of the best treatments for COVID-19,” said Anthony Gordon, M.D., Professor of Anaesthesia and Critical Care at Imperial College London and an NIHR Research Professor. “We will continue to publicly share what we learn from these trial platforms as fast as possible.”
REMAP-CAP is a nationally prioritised adaptive platform study investigating community-acquired pneumonia, a syndrome where people develop an acute infection of the lungs before being admitted to hospital. Bacterial and viral infections – like COVID-19 – are responsible for the vast majority of cases of community-acquired pneumonia.
REMAP-CAP continues to evaluate multiple other study questions, including therapeutic anticoagulation, antiplatelets, apremilast, eritoran, anakinra, sarilumab, vitamin C, simvastatin, convalescent plasma, macrolides and antibiotics.
More information on the study is available on the REMAP-CAP website.
Read about the research in a case study on the NIHR website.